arrow
J

Justin R. Ortiz

University of Maryland
H指数:45
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-in-Human Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella flexneri 2a Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122

首次人体安全性、遗传稳定性和免疫原性评价:表达产肠毒素大肠杆菌抗原的减毒志贺氏菌2a活载体疫苗株CVD 1208S-122

2026-07-150
PRE
An intranasal adjuvanted, recombinant influenza A/H5 vaccine primes against diverse H5N1 clades: a phase I trial

一种鼻内佐剂重组甲型流感病毒A/H5疫苗可针对多种H5N1亚系产生初始免疫应答:一项I期临床试验

2025-11-060
OAAI
The Global Influenza Hospital Surveillance Network: A Multicountry Public Health Collaboration

全球流感医院监测网络:一项多国公共卫生合作

2025-03-130
OAAI
Severity Scale of Influenza and Acute Respiratory Illness Hospitalizations to Support Viral Genomic Surveillance: A Global Influenza Hospital Surveillance Network Pilot Study

流感及急性呼吸道疾病住院严重程度量表,以支持病毒基因组监测:一项全球流感住院监测网络试点研究

2025-03-060
OAAI
Relative Effectiveness of the MF59®-Adjuvanted Influenza Vaccine Versus High-Dose and Non-Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019-2020 US Influenza Season

MF59的相对有效性®-在2019 2020的美国流感季节,含佐剂流感疫苗与高剂量和无佐剂流感疫苗在预防心肺住院中的作用

2024-04-212
OA
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial

不同启动方案后延迟异源禽流感a (H7N9) 疫苗加强的安全性和免疫原性: 一项随机临床试验

2023-07-193
OA
Age Differences in Comorbidities, Presenting Symptoms, and Outcomes of Influenza Illness Requiring Hospitalization: A Worldwide Perspective From the Global Influenza Hospital Surveillance Network

需要住院治疗的流感疾病的合并症、症状和结局的年龄差异: 全球流感医院监测网络的全球视角

2023-05-0711
OAAI
A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy Adults

健康成人甲型H1N1流感pdm09多中心对照人类感染研究

2023-01-265
OA